Investigating how beta-blockers can help reduce cravings in smokers
Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms
['FUNDING_R01'] · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · NIH-11056865
This study is looking at how a medication called propranolol might help people quit smoking by easing cravings that come from certain triggers in their environment, and it’s designed for smokers who want extra support alongside their usual quitting methods.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR (nih funded) |
| Locations | 1 site (OKLAHOMA CITY, UNITED STATES) |
| Trial ID | NIH-11056865 on ClinicalTrials.gov |
What this research studies
This research explores the use of beta-adrenergic receptor antagonists, specifically propranolol, to help individuals quit smoking by reducing cravings triggered by environmental cues. The study aims to understand how these medications can work alongside traditional smoking cessation treatments to improve outcomes. By examining neural responses and behavioral changes in smokers, the research seeks to identify effective strategies for enhancing smoking cessation efforts. Participants may receive a combination of medications to address both nicotine withdrawal and cue-induced cravings.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are attempting to quit smoking and experience cravings triggered by environmental cues.
Not a fit: Patients who are not smokers or who do not experience cravings related to smoking cues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective smoking cessation treatments that significantly reduce relapse rates among smokers.
How similar studies have performed: Previous studies have shown promising results using beta-blockers for addiction treatment, indicating potential for success in this novel approach.
Where this research is happening
OKLAHOMA CITY, UNITED STATES
- UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR — OKLAHOMA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OLIVER, JASON ANTHONY — UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- Study coordinator: OLIVER, JASON ANTHONY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: addictive disorder